IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on IDEXX Laboratories, with six buy ratings and four holds among 10 covering brokerages. The average 12-month price target is $747, though recent targets ranged from $670 to $710.
• IDEXX shares opened at $550.96, down 2.8%, and remain well below their 52-week high of $769.98. The stock trades at a price-to-earnings ratio of 38.75.
• The company exceeded quarterly expectations, reporting $4.27 in EPS versus the $3.94 consensus and $1.22 billion in revenue, up 9.7% year over year. Management issued fiscal 2026 EPS guidance of $14.69–$14.94.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $747.00.

IDXX has been the subject of several recent analyst reports. Barclays decreased their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research note on Tuesday. UBS Group raised their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday, July 29th. Citigroup upped their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th.

IDEXX Laboratories Stock Down 2.8%

IDEXX Laboratories stock opened at $550.96 on Friday. The stock has a market cap of $43.40 billion, a PE ratio of 38.75, a P/E/G ratio of 2.94 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock's fifty day moving average is $561.04 and its two-hundred day moving average is $581.51. IDEXX Laboratories has a 1-year low of $518.55 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. During the same period in the prior year, the firm posted $3.50 EPS. The business's quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts expect that IDEXX Laboratories will post 14.81 EPS for the current fiscal year.

Hedge Funds Weigh In On IDEXX Laboratories

Several hedge funds have recently made changes to their positions in the company. Elyxium Wealth LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $3,666,459,000. State Street Corp grew its stake in IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company's stock worth $2,473,817,000 after buying an additional 138,956 shares during the last quarter. J. Stern & Co. LLP increased its position in IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after buying an additional 2,642,200 shares during the period. Geode Capital Management LLC increased its position in IDEXX Laboratories by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company's stock worth $1,749,380,000 after buying an additional 86,263 shares during the period. Finally, Invesco Ltd. lifted its stake in IDEXX Laboratories by 13.8% in the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company's stock valued at $1,016,296,000 after buying an additional 181,955 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source